| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017760594 |
| P356 | DOI | 10.1007/S11523-015-0368-7 |
| P698 | PubMed publication ID | 25922090 |
| P2093 | author name string | Apar Kishor Ganti | |
| Ketki Tendulkar | |||
| Anum Abbas | |||
| Mohsin M Mirza | |||
| P2860 | cites work | VEGF inhibition and renal thrombotic microangiopathy | Q24632792 |
| Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis | Q27003304 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| ROS1 rearrangements define a unique molecular class of lung cancers | Q27851700 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption | Q28212198 | ||
| Cellular functions regulated by Src family kinases | Q29616038 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| HIF activation protects from acute kidney injury | Q33318643 | ||
| Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature | Q33416857 | ||
| Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer | Q33504234 | ||
| Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment | Q33638344 | ||
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors | Q33828690 | ||
| Role of nitric oxide in the control of renal function and salt sensitivity | Q34028209 | ||
| Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment | Q34127899 | ||
| The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response | Q34303766 | ||
| Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases | Q34835409 | ||
| Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study | Q40218225 | ||
| Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. | Q40229471 | ||
| Observations in experimental magnesium depletion | Q40310072 | ||
| Renal magnesium handling: new insights in understanding old problems | Q40879258 | ||
| Inhibition of MTOR disrupts autophagic flux in podocytes | Q41812610 | ||
| Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury | Q42047722 | ||
| Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors | Q42635174 | ||
| A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects | Q43224567 | ||
| Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy | Q44412574 | ||
| Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia | Q44548386 | ||
| Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma | Q44916136 | ||
| Sirolimus interacts with pathways essential for podocyte integrity | Q45151652 | ||
| ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis | Q45197190 | ||
| Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib | Q46143615 | ||
| VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature | Q46231250 | ||
| Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia | Q46332211 | ||
| Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany | Q46345626 | ||
| Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss | Q46794206 | ||
| Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. | Q46803794 | ||
| Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. | Q51604310 | ||
| Cetuximab-induced hypomagnesemia in patients with colorectal cancer. | Q53589575 | ||
| Vemurafenib significantly decreases glomerular filtration rate. | Q54394838 | ||
| All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. | Q54494865 | ||
| Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors? | Q54568070 | ||
| Arteriolar rarefaction in the conjunctiva of human essential hypertensives | Q54578705 | ||
| Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. | Q55069908 | ||
| Anti-CTLA4 antibody-induced lupus nephritis | Q56900027 | ||
| Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria | Q58214894 | ||
| Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate | Q60021753 | ||
| Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis | Q71566017 | ||
| Mediation of renal cyst formation by hepatocyte growth factor | Q72691450 | ||
| VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells | Q74408747 | ||
| Hypertension: a disease of the microcirculation? | Q79294433 | ||
| Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 | Q80088244 | ||
| Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer | Q87169945 | ||
| Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients | Q87691575 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q88151876 | ||
| Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan | Q95576015 | ||
| Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. | Q34943606 | ||
| Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome | Q35027295 | ||
| Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway | Q35058837 | ||
| FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma | Q35584012 | ||
| Complex renal cysts associated with crizotinib treatment | Q35755397 | ||
| Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. | Q35848463 | ||
| Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia | Q35916097 | ||
| Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study | Q36244233 | ||
| VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade | Q36276765 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies | Q36714379 | ||
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
| Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension | Q36894975 | ||
| Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence | Q36936421 | ||
| Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. | Q36986804 | ||
| Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia | Q37044749 | ||
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 | ||
| Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. | Q37077459 | ||
| Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis | Q37161889 | ||
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 | ||
| Managing patients with metastatic colorectal cancer on bevacizumab | Q37316862 | ||
| Management of hypertension in angiogenesis inhibitor-treated patients | Q37371312 | ||
| FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer | Q37413858 | ||
| Renal effects of anti-angiogenesis therapy: update for the internist | Q37426881 | ||
| Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature | Q37565808 | ||
| VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management | Q37652874 | ||
| Acute renal failure under dasatinib therapy | Q37683786 | ||
| Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies | Q37917796 | ||
| Dasatinib-induced nephrotic-range proteinuria | Q38094188 | ||
| Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. | Q38183333 | ||
| Strategies for the management of adverse events associated with mTOR inhibitors | Q38200765 | ||
| Kidney injuries related to ipilimumab | Q38200955 | ||
| Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. | Q39514813 | ||
| Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway | Q39703837 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 487-499 | |
| P577 | publication date | 2015-04-30 | |
| P1433 | published in | Targeted oncology | Q25378200 |
| P1476 | title | Renal Toxicities of Targeted Therapies | |
| P478 | volume | 10 |
| Q94046670 | A retrospective study of proteinuria in dogs receiving toceranib phosphate |
| Q93036029 | Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study |
| Q90527131 | Bevacizumab-associated glomerular microangiopathy |
| Q33895581 | Biological agents in gastrointestinal cancers: adverse effects and their management |
| Q37029899 | Comorbidity in older adults with cancer. |
| Q38816063 | Delivery of bevacizumab to atheromatous porcine carotid tissue using echogenic liposomes |
| Q64068821 | Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity |
| Q50209212 | Management of the toxicities of common targeted therapeutics for gynecologic cancers |
| Q42291179 | Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab |
| Q54213691 | Receptor tyrosine kinase KIT: Prognostic and therapeutic involvement in canine mast cell tumours. |
| Q55360813 | Research progress on common adverse events caused by targeted therapy for colorectal cancer. |
| Q39233631 | Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. |
Search more.